This technology identifies two genes that are fused in glioblastoma multiforme (brain cancer) and can be targeted to inhibit tumor growth.
Glioblastoma multiforme (GBM) is the most common form of brain cancer, and is also among the most incurable and lethal of all human cancers. Current methods to treat GBM include surgery, chemotherapy, and radiation therapy. However, none of these therapies specifically target GBM, and as such, the prognosis of GBM remains poor.
This technology identifies a highly expressed class of gene fusions in GBM, which join the tyrosine kinase domain of FGFR genes to the TACC domain of TACC1 or TACC3, resulting in FGFR-TACC1 or FGFR-TACC3 fusion proteins. This technology is the first identification of specific oncogenic gene fusions in GBM, which can serve as potential drug targets for its treatment via inhibition of FGRF kinase activity.
The technology was validated in cell lines and mouse models.
IR CU12240
Licensing Contact: Kristin Neuman